Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 2/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 2/20 | 0.35 |
| ▸ | JAK1 | P23458 | 2/20 | 0.35 |
| ▸ | ATR | Q13535 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.33 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.33 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.32 |
| ▸ | RXRA | P19793 | 2/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38653841 | 0.87 | OPRM1 (0.33) | — | |
| SCHEMBL30867803 | 0.87 | ACACB (0.35) | ACACBMAP4K4JAK2JAK1GPR119 | |
| SCHEMBL30867740 | 0.86 | POLB (0.40) | POLBACACBMAP4K4JAK2JAK1 | |
| SCHEMBL30868167 | 0.86 | POLB (0.40) | POLBACACBMAP4K4JAK2JAK1 | |
| SCHEMBL30867758 | 0.69 | GPR119 (0.38) | MAP4K4GPR119EIF2AK4GRM5HDAC1 | |
| SCHEMBL31169223 | 0.68 | GPR119 (0.38) | POLBACACBMAP4K4JAK2JAK1 | |
| SCHEMBL31734998 | 0.67 | DRD2 (0.52) | — | |
| SCHEMBL23578904 | 0.67 | EPHX2 (0.37) | ACACBJAK2JAK1 | |
| SCHEMBL31756246 | 0.67 | EPHX2 (0.37) | ACACBJAK2JAK1 | |
| SCHEMBL30532870 | 0.67 | EPHX2 (0.37) | ACACBJAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132143-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4598917-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | Amgen Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| WO-2024076674-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2024-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132143-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | KRAS, NRAS, HRAS | POLB 2718/4885ACACB 757/4885MAP4K4 2295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.